Guidelines for the diagnosis and treatment of peripheral occlusive artery disease (POAD);Leitlinien zur diagnostik und therapie der peripheren arteriellen verschlusskrankheit (PAVK)

Vasa - Journal of Vascular Diseases

Volumn 38, Issue SUPPL. 75, 2009, Pages 4-75

  Lawall, Holger ^a   Diehm, Curt ^a   Pittrow, David ^a   Trampisch, Hans J ^a   Huppert, Peter ^a   Stiegler, Hubert ^a   Tacke, Josef ^a   Rümenapf, Gerhard ^a   Heidrich, Heinz ^a   Schulte, Karl Ludwig ^a   Schmiedt, Walther ^a   Balzer, Klaus ^a   Schmidt Trucksäss, Arno ^a   Ott, Notburga ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC PROCEDURE; HUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; REVIEW; TREATMENT INDICATION;

EID: 79551609386     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (238)

1. Diehm C, Heidrich H, Schulte K, Spengel FA, Theiss W, Deutsche Gesellschaft für Angiologie, Gesellschaft für Gefäßmedizin. Leitlinien zur Diagnostik und Therapie der arteriellen Verschlusskrankheit der Beinarterien. VASA 2001;30(Suppl. 57): 1-20.
2. Norgren L, Hiatt W, Dormandy J, Nehler M, Harris K, Fowkes F. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007;33(Suppl. 1): S1-S75. (Pubitemid 46068992)
3. Hirsch AT, Haskal Z, Hertzer N, et al. ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). Circulation 2006;113: 463-654.
4. American Diabetes Association. Peripheral Arterial Disease in People With Diabetes. Diabetes Care 2003;26(12): 3333-41.
5. Arzneimittelkommission der deutschen Ärzteschaft. Handlungsleitlinie pAVK aus Empfehlungen zur Therapie der peripheren arteriellen Verschlusskrankheit (3. Auflage). Arzneiverordnung in der Praxis, Band 31, Sonderheft 3, Juli 2004.
6. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Werkzeuge für Leitlinien-Erstellung und -Aktualisierung. Internet: http: //www.uniduesseldorf.de/AWMF/ll/index.html. Zugriff am 5.11.2008.
7. Duvall WL, Vorchheimer DA. Multi-bed vascular disease and atherothrombosis: scope of the problem. J Thromb Thrombolysis 2004;17(1): 51-61.
8. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71(3): 510-5.
9. Diehm C, Schuster A, Allenberg H, Darius H, Haberl R, Lange S, Pittrow D, von Stritzky B, Tepohl G, Trampisch H. High prevalence of peripheral arterial disease and comorbidity in 6,880 primary care patients: cross sectional study. Atherosclerosis 2004;172: 95-105. (Pubitemid 38058606)
10. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991;20(2): 384-92.
11. Diehm C, Allenberg J-R, Haberl R, Darius H, Mahn M, Tepohl G, Holland-Letz T, Pittrow D, Trampisch H-J. High All-Cause Mortality in Patients with Peripheral Arterial Disease in Primary Care: Five-Year Results of the getABI Study [abstract 3701]. Circulation 2007;116(16-MeetingAbstracts): II-841-b.
12. Darius H, Trampisch H, Pittrow D, Allenberg J, Haberl R, Mahn M, Tepohl G, Burghaus I, Diehm C. Vergleich zweier Koronaräquivalente: Risikoerhöhung unter Diabetes mellitus und Peripherer Arterieller Verschlusskrankheit. DMW 2008;45: 2317-22.
13. Kroger K, Stang A, Kondratieva J, Moebus S, Beck E, Schmermund A, Mohlenkamp S, Dragano N, Siegrist J, Jockel KH, Erbel R. Prevalence of peripheral arterial disease - results of the Heinz Nixdorf recall study. Eur J Epidemiol 2006;21(4): 279-85. (Pubitemid 43725485)
14. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286(11): 1317-24.
15. Criqui MH, Vargas V, Denenberg JO, Ho E, Allison M, Langer RD, Gamst A, Bundens WP, Fronek A. Ethnicity and peripheral arterial disease: the San Diego Population Study. Circulation 2005;112(17): 2703-7.
16. Kullo IJ, Bailey KR, Kardia SLR, Mosley TH, Jr., Boerwinkle E, Turner ST. Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study. Vascular Medicine 2003;8(4): 237-42.
17. Kannel WB. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1994;1(4): 333-9.
18. Wilterdink JL, Easton JD. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol 1992;49(8): 857-63.
19. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89(3): 1333-445.
20. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326(6): 381-6.
21. Wolfe J. Defining the outcome of critical ischaemia: a one year prospective study. Br J Surg 1986;73: 321.
22. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, Fowkes FG, Gillepsie I, Ruckley CV, Raab G, Storkey H. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 2005;366(9501): 1925-34. (Pubitemid 41713982)
23. Fratezi AC, Albers M, De Luccia ND, Pereira CA. Outcome and quality of life of patients with severe chronic limb ischaemia: a cohort study on the influence of diabetes. Eur J Vasc Endovasc Surg 1995;10(4): 459-65.
24. Steg PG, Bhatt DL, Wilson PW, D'Agostino R, Sr., Ohman EM, Rother J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297(11): 1197-206.
25. Pittrow D, Trampisch HJ, Paar WD, Mahn M, Haberl R, Darius H, Tepohl G, Endres H, Allenberg JR, Diehm C. Gravierende Unterschiede in der medikamentösen Versorgung: PAVK-Patienten im Vergleich zu KHK-Patienten deutlich benachteiligt. Cardiovasc 2007;5: 36-9.
26. Allenberg J, Trampisch H, Darius H, Lange S, Haberl R, v. Stritzky B, Tepohl G, Pittrow D, Diehm C. Prävalenz, Komorbidität und Behandlungsintensität der peripheren arteriellen Verschlusskrankheit in der Hausarztpraxis. Ergebnisse der getABI-Studie. Gefäßchirurgie 2004;9(3): 166-71.
27. Lange S, Diehm C, Darius H, Haberl R, Allenberg JR, Pittrow D, Schuster A, von Stritzky B, Tepohl G, Trampisch HJ. High prevalence of peripheral arterial disease and low treatment rates in elderly primary care patients with diabetes. Exp Clin Endocrinol Diabetes 2004;112(10): 566-73.
28. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas J-L, Goto S, Liau C-S, Richard AJ, Rother J, Wilson PWF, for the RRI. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis. JAMA 2006;295(2): 180-9.
29. Hirsch AT, Murphy TP, Lovell MB, Twillman G, Treat-Jacobson D, Harwood EM, Mohler ER, 3rd, Creager MA, Hobson RW, 2nd, Robertson RM, Howard WJ, Schroeder P, Criqui MH. Gaps in public knowledge of peripheral arterial disease: the first national PAD public awareness survey. Circulation 2007;116(18): 2086-94.
30. Khan NA, Rahim SA, Anand SS, Simel DL, Panju A. Does the Clinical Examination Predict Lower Extremity Peripheral Arterial Disease? JAMA 2006;295(5): 536-46.
31. Da Silva A, Widmer L. Occlusive peripheral artery disease. Early diagnosis, incidence, course, significance. Hans Huber. Bern, Stuttgart, Wien. 1980. S.1-97.
32. Boulton AJ, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med 1998;15(6): 508-14.
33. Levin ME. Preventing amputation in the patient with diabetes. Diabetes Care 1995;18(10): 1383-94.
34. Salonen R, Nyyssonen K, Porkkala E, Rummukainen J, Belder R, Park JS, Salonen JT. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995;92(7): 1758-64.
35. Diehm C, Darius H, Pittrow D, Allenberg J. Der Knöchel-Arm-Index: ein wegweisender Risikomarker für die hausärztliche Praxis. Dt Ärzteblatt 2005;102(34): A2310-3.
36. Tsai AW, Folsom AR, Rosamond WD, Jones DW. Ankle-Brachial Index and 7-Year Ischemic Stroke Incidence: The ARIC Study. Stroke 2001;32(8): 1721-4.
37. Ogren M, Hedblad B, Engstrom G, Janzon L. Prevalence and prognostic significance of asymptomatic peripheral arterial disease in 68-year-old men with diabetes. Results from the population study ,Men born in 1914' from Malmo, Sweden. Eur J Vasc Endovasc Surg 2005;29(2): 182-9. (Pubitemid 40104009)
38. Schröder F, Diehm N, Kareem S, Ames M, Pira A, Zwettler U, Lawall H, Diehm C. A modified calculation of ankle-brachial pressure index is far more sensitive in the detection of peripheral arterial disease. J Vasc Surg 2006;44(3): 531-6.
39. Espinola-Klein C, Rupprecht HJ, Bickel C, Lackner K, Savvidis S, Messow CM, Munzel T, Blankenberg S. Different calculations of ankle-brachial index and their impact on cardiovascular risk prediction. Circulation 2008;118(9): 961-7.
40. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM, Jr., White CJ, White J, White RA, Antman EM, Smith SC, Jr., Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113(11): e463-654.
41. Diehm C, Lange S, Darius H, Pittrow D, von Stritzky B, Tepohl G, Haberl RL, Allenberg JR, Dasch B, Trampisch HJ. Association of low ankle brachial index with high mortality in primary care. Eur Heart J 2006;27(14): 1743-9.
42. Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: morbidity and mortality implications. Circulation 2006;114(7): 688-99.
43. Rose SC. Noninvasive vascular laboratory for evaluation of peripheral arterial occlusive disease: Part II - clinical applications: chronic, usually atherosclerotic, lower extremity ischemia. J Vasc Interv Radiol 2000;11(10): 1257-75.
44. Holland-Letz T, Endres HG, Biedermann S, Mahn M, Kunert J, Groh S, Pittrow D, von Bilderling P, Sternitzky R, Diehm C. Reproducibility and reliability of the ankle-brachial index as assessed by vascular experts, family physicians and nurses. Vasc Med 2007;12(2): 105-12. (Pubitemid 46995473)
45. Hoogeveen EK, Mackaay AJ, Beks PJ, Kostense PJ, Dekker JM, Heine RJ, Nijpels G, Rauwerda JA, Stehouwer CD. Evaluation of the one-minute exercise test to detect peripheral arterial disease. Eur J Clin Invest 2008;38(5): 290-5.
46. Smith FC, Shearman CP, Simms MH, Gwynn BR. Falsely elevated ankle pressures in severe leg ischaemia: the pole test - an alternative approach. Eur J Vasc Surg 1994;8(4): 408-12.
47. Spronk S, den Hoed PT, de Jonge LC, van Dijk LC, Pattynama PM. Value of the duplex waveform at the common femoral artery for diagnosing obstructive aortoiliac disease. J Vasc Surg 2005;42(2): 236-42; discussion 42.
48. Zwicky S, Mahler F, Baumgartner I. Evaluation of clinical tests to assess perfusion in chronic critical limb ischemia. Vasa 2002;31(3): 173-8. (Pubitemid 34912875)
49. Collins R, Burch J, Cranny G, Aguiar-Ibanez R, Craig D, Wright K, Berry E, Gough M, Kleijnen J, Westwood M. Duplex ultrasonography, magnetic resonance angiography, and computed tomography angiography for diagnosis and assessment of symptomatic, lower limb peripheral arterial disease: systematic review. Bmj 2007;334(7606): 1257.
50. Schlager O, Francesconi M, Haumer M, Dick P, Sabeti S, Amighi J, Mlekusch W, Koppensteiner R, Minar E, Schillinger M. Duplex sonography versus angiography for assessment of femoropopliteal arterial disease in a "real-world" setting. J Endovasc Ther 2007;14(4): 452-9.
51. Bostrom A, Karacagil S, Lofberg AM, Ljungman C, Nyman R, Logason K, Hellberg A. Selection of patients with lower limb arterial occlusive disease for endovascular treatment of the iliac arteries with duplex scanning. Vasc Surg 2001;35(6): 437-42.
52. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000;102(13): 1503-10.
53. Ranke C, Creutzig A, Alexander K. Duplex scanning of the peripheral arteries: correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound Med Biol 1992;18(5): 433-40.
54. Ouwendijk R, Kock MC, van Dijk LC, van Sambeek MR, Stijnen T, Hunink MG. Vessel wall calcifications at multi-detector row CT angiography in patients with peripheral arterial disease: effect on clinical utility and clinical predictors. Radiology 2006;241(2): 603-8. (Pubitemid 44632909)
55. Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med 2006;354(4): 379-86.
56. Parfrey P. The clinical epidemiology of contrast-induced nephropathy. Cardiovasc Intervent Radiol 2005;28 Suppl 2: S3-11.
57. Nguyen SA, Suranyi P, Ravenel JG, Randall PK, Romano PB, Strom KA, Costello P, Schoepf UJ. Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function. Radiology 2008;248(1): 97-105.
58. Weisbord SD, Palevsky PM. Radiocontrast-induced acute renal failure. J Intensive Care Med 2005;20(2): 63-75.
59. Lee JK, Warshauer DM, Bush WH, Jr., McClennan BL, Choyke PL. Determination of serum creatinine level before intravenous administration of iodinated contrast medium. A survey. Invest Radiol 1995;30(12): 700-5.
60. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139(2): 137-47.
61. Leiner T, Herborn CU, Goyen M. Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide. Eur Radiol 2007;17(8): 1921-3. (Pubitemid 47097447)
62. Gjonnaess E, Morken B, Sandbaek G, Stranden E, Slagsvold CE, Jorgensen JJ, Nylaende M, Abdelnoor M, Dullerud R. Gadolinium-enhanced magnetic resonance angiography, colour duplex and digital subtraction angiography of the lower limb arteries from the aorta to the tibio-peroneal trunk in patients with intermittent claudication. Eur J Vasc Endovasc Surg 2006;31(1): 53-8. (Pubitemid 43024984)
63. Nationale Versorgungsleitlinie (NVL) Typ-2-Diabetes. 2. Au- flage 2006. Internet: http: //www.diabetes.versorgungsleitlinien.de/. Zugriff am 6.12.2008.
64. Heikkinen M, Salmenpera M, Lepantalo A, Lepantalo M. Diabetes care for patients with peripheral arterial disease. Eur J Vasc Endovasc Surg 2007;33(5): 583-91. (Pubitemid 46552916)
65. Ouriel K. Peripheral arterial disease. Lancet 2001;358(9289): 1257-64.
66. Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Medical management of peripheral arterial disease. J Thromb Haemost 2005;3(8): 1628-37.
67. Jamsen TS, Manninen HI, Tulla HE, Jaakkola PA, Matsi PJ. Infrainguinal revascularization because of claudication: total long-term outcome of endovascular and surgical treatment. J Vasc Surg 2003;37(4): 808-15.
68. Kudo T, Chandra FA, Kwun WH, Haas BT, Ahn SS. Changing pattern of surgical revascularization for critical limb ischemia over 12 years: endovascular vs. open bypass surgery. J Vasc Surg 2006;44(2): 304-13. (Pubitemid 44142917)
69. Bockler D, Blaurock P, Mansmann U, Schwarzbach M, Seelos R, Schumacher H, Allenberg JR. Early surgical outcome after failed primary stenting for lower limb occlusive disease. J Endovasc Ther 2005;12(1): 13-21. (Pubitemid 40229384)
70. Conte MS, Belkin M, Upchurch GR, Mannick JA, Whittemore AD, Donaldson MC. Impact of increasing comorbidity on infrainguinal reconstruction: a 20-year perspective. Ann Surg 2001;233(3): 445-52. (Pubitemid 32187826)
71. van der Feen C, Neijens FS, Kanters SD, Mali WP, Stolk RP, Banga JD. Angiographic distribution of lower extremity atherosclerosis in patients with and without diabetes. Diabet Med 2002;19(5): 366-70.
72. Panayiotopoulos YP, Tyrrell MR, Arnold FJ, Korzon-Burakowska A, Amiel SA, Taylor PR. Results and cost analysis of distal [crural/pedal] arterial revascularisation for limb salvage in diabetic and non-diabetic patients. Diabet Med 1997;14(3): 214-20. (Pubitemid 27151834)
73. Dorros G, Jaff MR, Dorros AM, Mathiak LM, He T. Tibioperoneal (outflow lesion) angioplasty can be used as primary treatment in 235 patients with critical limb ischemia: five-year follow-up. Circulation 2001;104(17): 2057-62. (Pubitemid 33027046)
74. Holstein P, Ellitsgaard N, Olsen BB, Ellitsgaard V. Decreasing incidence of major amputations in people with diabetes. Diabetologia 2000;43(7): 844-7. (Pubitemid 30463162)
75. Greenhalgh RM. Towards vascular and endovascular consensus. 2005. Internet: www.cxvascular.com/CXsymp/CXsymp.cfm.Zugriff am 1.11.2008.
76. Al-Omran M, Tu JV, Johnston KW, Mamdani MM, Kucey DS. Use of interventional procedures for peripheral arterial occlusive disease in Ontario between 1991 and 1998: a population-based study. J Vasc Surg 2003;38(2): 289-95.
77. Wattanakit K, Williams JE, Schreiner PJ, Hirsch AT, Folsom AR. Association of anger proneness, depression and low social support with peripheral arterial disease: the Atherosclerosis Risk in Communities Study. Vasc Med 2005;10(3): 199-206.
78. Hirsch AT, Treat-Jacobson D, Lando HA, Hatsukami DK. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc Med 1997;2(3): 243-51. (Pubitemid 27468159)
79. Willigendael EM, Teijink JA, Bartelink ML, Kuiken BW, Boiten J, Moll FL, Buller HR, Prins MH. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg 2004;40(6): 1158-65.
80. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340(9): 685-91.
81. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2003;360: 7-22.
82. Pedersen TR, Kjekshus J, Pyorala K, Olsson AG, Cook TJ, Musliner TA, Tobert JA, Haghfelt T. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998;81(3): 333-5.
83. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: arandomisedplacebo-controlled trial. Lancet 2003; 361(9374): 2005-16.
84. Egan DA, Garg R, Wilt TJ, Pettinger MB, Davis KB, Crouse J, Herd JA, Hunninghake DB, Sheps DS, Kostis JB, Probstfield J, Waclawiw MA, Applegate W, Elam MB. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. Am J Cardiol 1999;83(4): 569-75.
85. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110(23): 3512-7.
86. Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJM, Holman RR. UKPDS 59: Hyperglycemia and Other Potentially Modifiable Risk Factors for Peripheral Vascular Disease in Type 2 Diabetes. Diabetes Care 2002;25(5): 894-9. (Pubitemid 41094289)
87. Dolan NC, Liu K, Criqui MH, Greenland P, Guralnik JM, Chan C, Schneider JR, Mandapat AL, Martin G, McDermott MM. Peripheral artery disease, diabetes, and reduced lower extremity functioning. Diabetes Care 2002;25(1): 113-20.
88. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348(5): 383-93.
89. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jonsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyorala K, Raz I, Schernthaner G, Volpe M, Wood D. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28(1): 88-136. (Pubitemid 46137814)
90. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med 2008;359(15): 1577-89.
91. The ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358: 2545-59.
92. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358: 2560-72.
93. Veterans Affairs Diabetes Trial (VADT) Study Group, ADA Scientific Sessions on June 8, 2008.
94. Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive Blood Pressure Control Reduces the Risk of Cardiovascular Events in Patients With Peripheral Arterial Disease and Type 2 Diabetes. Circulation 2003;107(5): 753-6. (Pubitemid 36222605)
95. Hoeks SE, Scholte Op Reimer WJ, van Urk H, Jorning PJ, Boersma E, Simoons ML, Bax JJ, Poldermans D. Increase of 1-year mortality after perioperative beta-blocker withdrawal in endovascular and vascular surgery patients. Eur J Vasc Endovasc Surg 2007;33(1): 13-9.
96. Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Malaga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371(9627): 1839-47.
97. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl): 381S-453S.
98. Sobel M, Verhaeghe R. Antithrombotic Therapy for Peripheral Artery Occlusive Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6-suppl): 815S-43.
99. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O'Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Bmj 2008;337: a1840.
100. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J 2002;324: 71-86.
101. Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, Persson G, Almgren B, Fagher B, Kjellstrom T, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990;227(5): 301-8. (Pubitemid 20137140)
102. Clagett GP, Sobel M, Jackson MR, Lip GY, Tangelder M, Verhaeghe R. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl): 609S-26S.
103. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348(9038): 1329-39.
104. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354(16): 1706-17.
105. Programm für Nationale Versorgungsleitlinien. Chronische KHK. Internet: http: //www.versorgungsleitlinien.de/themen/khk/index-html. Zugriff am 6.12.2008.
106. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, Pierpont G, Santilli S, Rapp J, Hattler B, Shunk K, Jaenicke C, Thottapurathu L, Ellis N, Reda DJ, Henderson WG. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 2004;351(27): 2795-804.
107. Gemeinsame Leitlinie der Deutschen Gesellschaft für Neurologie (DGN) und der Deutschen Schlaganfallgesellschaft (DSG). Primäre und sekundäre Prävention der zerebralen Ischämie. DGN/DGS 2005. Internet: http://www.dgn.org/127.0.html.Zugriff am 6. Juni 2008.
108. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001;344(21): 1608-21.
109. Steinacker J, Liu Y, Hanke H. Körperliche Bewegung bei peripherer arterieller Verschlusskrankheit. Deutsches Ärzteblatt 2002;45: 2550-4.
110. Schulte K. Interventionelle endovaskuläre Therapie bei Patienten mit peripherer arterieller Verschlusskrankheit-Ballonangioplastie. VASA 2004;33(Suppl. 64): 5-7. (Pubitemid 38325504)
111. Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation 1994;90(4): 1866-74.
112. Gardner AW, Katzel LI, Sorkin JD, Bradham DD, Hochberg MC, Flinn WR, Goldberg AP. Exercise rehabilitation improves functional outcomes and peripheral circulation in patients with intermittent claudication: a randomized controlled trial. J Am Geriatr Soc 2001;49(6): 755-62.
113. Katzel LI, Sorkin JD, Powell CC, Gardner AW. Comorbidities and exercise capacity in older patients with intermittent claudication. Vasc Med 2001;6(3): 157-62.
114. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev 2000(2): CD000990.
115. Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev 2006(2): CD005263.
116. Amendt K. Ist der allgemein akzeptierte therapeutische Nutzen des Gehtrainings bei Patienten mit arterieller Verschlusskrankheit evidenzbasiert? Analyse des Cochrane-Reviews. Hämostaseologie 2006;26: 224-28.
117. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. N Engl J Med 2002;347(24): 1941-51.
118. De Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database Syst Rev 2008(2): CD001368.
119. Boccalon H, Lehert P, Mosnier M. [Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication]. Ann Cardiol Angiol (Paris) 2001;50(3): 175-82.
120. Regensteiner JG, Ware JE, Jr., McCarthy WJ, Zhang P, Forbes WP, Heckman J, Hiatt WR. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002;50(12): 1939-46.
121. Hiatt WR. The US experience with cilostazol in treating intermittent claudication. Atheroscler Suppl 2005;6(4): 21-31.
122. Bradbury AW. The role of cilostazol (Pletal) in the management of intermittent claudication. Int J Clin Pract 2003;57(5): 405-9.
123. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg 2008;47(2): 330-6.
124. Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol 2001;87(12A): 28D-33D.
125. Ishii H, Kumada Y, Toriyama T, Aoyama T, Takahashi H, Yamada S, Yasuda Y, Yuzawa Y, Maruyama S, Matsuo S, Matsubara T, Murohara T. Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease. Clin J Am Soc Nephrol 2008;3(4): 1034-40.
126. Iida O, Nanto S, Uematsu M, Morozumi T, Kotani J, Awata M, Onishi T, Ito N, Oshima F, Minamiguchi H, Kitakaze M, Nagata S. Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery. Circ J 2005;69(10): 1256-9.
127. Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM, Han KH, Lee CW, Kang DH, Song JK, Kim JJ, Park SJ. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005;46(10): 1833-7.
128. Creutzig A, Lehmacher W, Elze M. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV. Vasa 2004;33(3): 137-44. (Pubitemid 39141713)
129. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005;366(9498): 1719-24. (Pubitemid 41587452)
130. Harding KG, Morris HL, Patel GK. Science, medicine and the future: healing chronic wounds. Bmj 2002;324(7330): 160-3.
131. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC. Practice guidelines for the diagnosis and management of skin and softtissue infections. Clin Infect Dis 2005;41(10): 1373-406.
132. Menzonian J. Major leg amputations in patients with severe peripheral arterial occlusive disease (PAD) not amenable to revascularization procedures: results of a randomized, placebo-controlled multicenter study with alprostadil. 17th World Congress of the International Union of Angiology (IUA). Abstract book, London 1995; Seite 22.
133. Stiegler H, Diehm C, Grom E, Martin M, Morl H, Rudofsky G, Vogelberg KH. [Placebo controlled, double-blind study of the effectiveness of i.v. prostaglandin E1 in diabetic patients with stage IV arterial occlusive disease]. Vasa Suppl 1992;35: 164-6.
134. Altstaedt HO, Berzewski B, Breddin HK, Brockhaus W, Bruhn HD, Cachovan M, Diehm C, Dorrler J, Franke CS, Gruss JD, et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukot Essent Fatty Acids 1993;49(2): 573-8.
135. Loosemore TM, Chalmers TC, Dormandy JA. A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. Int Angiol 1994;13(2): 133-42.
136. Kalani M, Apelqvist J, Blomback M, Brismar K, Eliasson B, Eriksson JW, Fagrell B, Hamsten A, Torffvit O, Jorneskog G. Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: a prospective, randomized, double-blind, placebo-controlled study. Diabetes Care 2003;26(9): 2575-80.
137. Nikol S, Baumgartner I, Van Belle E, Diehm C, Visona A, Capogrossi MC, Ferreira-Maldent N, Gallino A, Wyatt MG, Wijesinghe LD, Fusari M, Stephan D, Emmerich J, Pompilio G, Vermassen F, Pham E, Grek V, Coleman M, Meyer F. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008;16(5): 972-8.
138. Satoaki M, Tetsuya T, Toyoaki M, Tsutomu I, Yousuke K, Masaaki I, Yoshihiko S, Shiro U, Hiroshi S, Shinya F, Yasutaka Y, Rie O, Satoshi T, Masanori F, Hiroaki M. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. American heart journal 2008;156(5): 1010.
139. Dormandy J, Rutherford R. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000;31(1 Pt 2): S1-S296.
140. Nasr MK, McCarthy RJ, Hardman J, Chalmers A, Horrocks M. The increasing role of percutaneous transluminal angioplasty in the primary management of critical limb ischaemia. Eur J Vasc Endovasc Surg 2002;23(5): 398-403. (Pubitemid 41079420)
141. Wagner HJ. [Current status of endovascular therapy in the femoropopliteal vascular segment in chronic peripheral arterial occlusive disease]. Vasa 2002;31(3): 153-61.
142. Garasic JM, Creager MA. Percutaneous interventions for lower-extremity peripheral atherosclerotic disease. Rev Cardiovasc Med 2001;2(3): 120-5.
143. Muradin GS, Bosch JL, Stijnen T, Hunink MG. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. Radiology 2001;221(1): 137-45.
144. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, Schlager O, Cejna M, Lammer J, Minar E. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006;354(18): 1879-88.
145. Soder HK, Manninen HI, Jaakkola P, Matsi PJ, Rasanen HT, Kaukanen E, Loponen P, Soimakallio S. Prospective trial of infrapopliteal artery balloon angioplasty for critical limb ischemia: angiographic and clinical results. J Vasc Interv Radiol 2000;11(8): 1021-31.
146. Balmer H, Mahler F, Do DD, Triller J, Baumgartner I. Balloon angioplasty in chronic critical limb ischemia: factors affecting clinical and angiographic outcome. J Endovasc Ther 2002;9(4): 403-10.
147. Lawall H, Diehm C. Update Angiology. Med Klin (Munich) 2008;103(4): 198-209.
148. Jamsen TS, Manninen HI, Jaakkola PA, Matsi PJ. Long-term outcome of patients with claudication after balloon angioplasty of the femoropopliteal arteries. Radiology 2002;225(2): 345-52.
149. Tetteroo E, van der Graaf Y, Bosch JL, van Engelen AD, Hunink MG, Eikelboom BC, Mali WP. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch Iliac Stent Trial Study Group. Lancet 1998;351(9110): 1153-9.
150. Klein WM, van der Graaf Y, Seegers J, Spithoven JH, Buskens E, van Baal JG, Buth J, Moll FL, Overtoom TT, van Sambeek MR, Mali WP. Dutch iliac stent trial: long-term results in patients randomized for primary or selective stent placement. Radiology 2006;238(2): 734-44. (Pubitemid 43134389)
151. Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology 1997;204(1): 87-96. (Pubitemid 27281713)
152. Ponec D, Jaff MR, Swischuk J, Feiring A, Laird J, Mehra M, Popma JJ, Donohoe D, Firth B, Keim E, Snead D. The Nitinol SMART stent vs Wallstent for suboptimal iliac artery angioplasty: CRISPUS trial results. J Vasc Interv Radiol 2004;15(9): 911-8.
153. Lugmayr HF, Holzer H, Kastner M, Riedelsberger H, Auterith A. Treatment of complex arteriosclerotic lesions with nitinol stents in the superficial femoral and popliteal arteries: a midterm follow-up. Radiology 2002;222(1): 37-43.
154. Jahnke T, Voshage G, Muller-Hulsbeck S, Grimm J, Heller M, Brossmann J. Endovascular placement of self-expanding nitinol coil stents for the treatment of femoropopliteal obstructive disease. J Vasc Interv Radiol 2002;13(3): 257-66.
155. Duda S, Heller S, Wiesinger B, Tepe G. Modifizierte Stents für die interventionelle Therapie der PAVK. VASA 2004;Suppl 64(33): 55-9.
156. Pozzi Mucelli F, Fisicaro M, Calderan L, Malacrea M, Mazzone C, Cattin L, Scardi S, Pozzi Mucelli R. Percutaneous revascularization of femoropopliteal artery disease: PTA and PTA plus stent. Results after six years' follow-up. Radiol Med (Torino) 2003;105(4): 339-49.
157. Comerota AJ. Endovascular and surgical revascularization for patients with intermittent claudication. Am J Cardiol 2001;87(12A): 34D-43D.
158. Tefera G, Turnipseed W, Tanke T. Limb salvage angioplasty in poor surgical candidates. Vasc Endovascular Surg 2003;37(2): 99-104. (Pubitemid 36373472)
159. Lofberg AM, Karacagil S, Ljungman C, Westman B, Bostrom A, Hellberg A, Ostholm G. Percutaneous transluminal angioplasty of the femoropopliteal arteries in limbs with chronic critical lower limb ischemia. J Vasc Surg 2001;34(1): 114-21.
160. Faglia E, Mantero M, Caminiti M, Caravaggi C, De Giglio R, Pritelli C, Clerici G, Fratino P, De Cata P, Dalla Paola L, Mariani G, Poli M, Settembrini PG, Sciangula L, Morabito A, Graziani L. Extensive use of peripheral angioplasty, particularly infrapopliteal, in the treatment of ischaemic diabetic foot ulcers: clinical results of a multicentric study of 221 consecutive diabetic subjects. J Intern Med 2002;252(3): 225-32.
161. Brillu C, Picquet J, Villapadierna F, Papon X, L'Hoste P, Jousset Y, Enon B. Percutaneous transluminal angioplasty for management of critical ischemia in arteries below the knee. Ann Vasc Surg 2001;15(2): 175-81.
162. Faglia E, Dalla Paola L, Clerici G, Clerissi J, Graziani L, Fusaro M, Gabrielli L, Losa S, Stella A, Gargiulo M, Mantero M, Caminiti M, Ninkovic S, Curci V, Morabito A. Peripheral angioplasty as the first-choice revascularization procedure in diabetic patients with critical limb ischemia: prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003. Eur J Vasc Endovasc Surg 2005;29(6): 620-7.
163. Sigala F, Georgopoulos S, Langer S, Baunach C, Papalambros E, Sigalas K, Bramis J, Bakoyiannis C, Bastounis E, Hepp W. Outcome of infrainguinal revascularization for critical limb ischemia in diabetics with end stage renal disease. Vasa 2006;35(1): 15-20.
164. Henry M, Klonaris C, Amor M, Henry I, Tzvetanov K. State of the art: which stent for which lesion in peripheral interventions? Tex Heart Inst J 2000;27(2): 119-26.
165. Arena FJ. Arterial kink and damage in normal segments of the superficial femoral and popliteal arteries abutting nitinol stents - a common cause of late occlusion and restenosis? A single-center experience. J Invasive Cardiol 2005;17(9): 482-6.
166. Avisse C, Marcus C, Ouedraogo T, Delattre JF, Menanteau B, Flament JB. Anatomo-radiological study of the popliteal artery during knee flexion. Surg Radiol Anat 1995;17(3): 255-62.
167. Babalik E, Gulbaran M, Gurmen T, Ozturk S. Fracture of popliteal artery stents. Circ J 2003;67(7): 643-5.
168. Scheinert D, Scheinert S, Sax J, Piorkowski C, Braunlich S, Ulrich M, Biamino G, Schmidt A. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005;45(2): 312-5.
169. Redberg RF, Greenland P, Fuster V, Pyorala K, Blair SN, Folsom AR, Newman AB, O'Leary DH, Orchard TJ, Psaty B, Schwartz JS, Starke R, Wilson PW. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group III: risk assessment in persons with diabetes. Circulation 2002;105(18): e144-52.
170. Heikkinen M, Salenius JP, Auvinen O. Projected workload for a vascular service in 2020. Eur J Vasc Endovasc Surg 2000;19(4): 351-5.
171. The Vascular Surgical Society of Great Britain and Ireland. Critical limb ischaemia: management and outcome. Report of a national survey. Eur J Vasc Endovasc Surg 1995;10(1): 108-13.
172. Murphy TP, Ariaratnam NS, Carney WI, Jr., Marcaccio EJ, Slaiby JM, Soares GM, Kim HM. Aortoiliac insufficiency: long-term experience with stent placement for treatment. Radiology 2004;231(1): 243-9.
173. de Vries SO, Hunink MG. Results of aortic bifurcation grafts for aortoiliac occlusive disease: a meta-analysis. J Vasc Surg 1997;26(4): 558-69.
174. Kechagias A, Ylonen K, Biancari F. Long-term outcome after isolated endarterectomy of the femoral bifurcation. World J Surg 2008;32(1): 51-4.
175. Bastounis E, Felekouras E, Pikoulis E, Hadjinikolaou L, Georgopoulos S, Balas P. The role of profunda femoris revascularization in aortofemoral surgery. An analysis of factors affecting graft patency. Int Angiol 1997;16(2): 107-13.
176. Hill DA, Jamieson CW. The results of arterial reconstruction utilizing the profunda femoris artery in the treatment of rest pain and pre-gangrene. Br J Surg 1977;64(5): 359-61.
177. Tangelder MJ, Algra A, Lawson JA, Eikelboom BC. Risk factors for occlusion of infrainguinal bypass grafts. Eur J Vasc Endovasc Surg 2000;20(2): 118-24.
178. Hunink MG, Wong JB, Donaldson MC, Meyerovitz MF, Harrington DP. Patency results of percutaneous and surgical revascularization for femoropopliteal arterial disease. Med Decis Making 1994;14(1): 71-81.
179. Gentile AT, Lee RW, Moneta GL, Taylor LM, Edwards JM, Porter JM. Results of bypass to the popliteal and tibial arteries with alternative sources of autogenous vein. J Vasc Surg 1996;23(2): 272-9; discussion 9-80.
180. Albers M, Battistella VM, Romiti M, Rodrigues AA, Pereira CA. Meta-analysis of polytetrafluoroethylene bypass grafts to infrapopliteal arteries. J Vasc Surg 2003;37(6): 1263-9.
181. Berglund J, Bjorck M, Elfstrom J. Long-term results of above knee femoro-popliteal bypass depend on indication for surgery and graft-material. Eur J Vasc Endovasc Surg 2005;29(4): 412-8.
182. Neufang A, Espinola-Klein C, Dorweiler B, Messow CM, Schmiedt W, Vahl CF. Femoropopliteal prosthetic bypass with glutaraldehyde stabilized human umbilical vein (HUV). J Vasc Surg 2007;46(2): 280-8.
183. Haider SN, Kavanagh EG, Forlee M, Colgan MP, Madhavan P, Moore DJ, Shanik GD. Two-year outcome with preferential use of infrainguinal angioplasty for critical ischemia. J Vasc Surg 2006;43(3): 504-12.
184. Albers M, Romiti M, Brochado-Neto FC, De Luccia N, Pereira CA. Meta-analysis of popliteal-to-distal vein bypass grafts for critical ischemia. J Vasc Surg 2006;43(3): 498-503.
185. Rümenapf G, Neufang A, Schmiedt W, Wölfle KD, Lang W. Gefäßchirurgie bei Diabetikern mit Fußproblemen. Dtsch Arztebl 2004;101(49): A-3348 / B-2835 / C-684.
186. Visser K, Idu MM, Buth J, Engel GL, Hunink MG. Duplex scan surveillance during the first year after infrainguinal autologous vein bypass grafting surgery: costs and clinical outcomes compared with other surveillance programs. J Vasc Surg 2001;33(1): 123-30.
187. Davies AH, Hawdon AJ, Sydes MR, Thompson SG. Is duplex surveillance of value after leg vein bypass grafting? Principal results of the Vein Graft Surveillance Randomised Trial (VGST). Circulation 2005;112(13): 1985-91.
188. Berridge DC, Kessel D, Robertson I. Surgery versus thrombolysis for acute limb ischaemia: initial management. Cochrane Database Syst Rev 2002(3): CD002784.
189. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann Surg 1994;220(3): 251-66; discussion 66-8.
190. Ouriel K, Shortell CK, DeWeese JA, Green RM, Francis CW, Azodo MV, Gutierrez OH, Manzione JV, Cox C, Marder VJ. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg 1994;19(6): 1021-30.
191. Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med 1998;338(16): 1105-11.
192. Deutsche Gesellschaft für Chirurgie, Deutsche Gesellschaft für Unfallchirurgie, Deutsche Gesellschaft für Orthopädie und orthopädische Chirurgie. Stationäre und ambulante Thromboembolie- Prophylaxe in der Chirurgie und der perioperativen Medizin. S2-Leitlinie. AWMF 003/001. Internet: http: //www.uni-duesseldorf.de/AWMF/ll/003-001.htm. Zugriff am 2.2.2009.
193. Deutsche Gesellschaft für Angiologie, Gesellschaft für Gefäßmedizin. Leitlinie zur Diagnostik und Therapie der Bein- und Beckenvenenthrombose und Lungenembolie. AWMF 065/002. Internet: http://www.angiologie-giessen.de/pdf/leitlinietvt.pdf. Zugriff am 6.12.2008.
194. Schillinger M, Exner M, Mlekusch W, Haumer M, Ahmadi R, Rumpold H, Wagner O, Minar E. Balloon Angioplasty and Stent Implantation Induce a Vascular Inflammatory Reaction. J Endovas Ther 2002;9: 59-66.
195. Schillinger M, Exner M, Mlekusch W, Haumer M, Ahmadi R, Rumpold H, Wagner O, Minar E. Inflammatory response to stent implantation: differences in femoropopliteal, iliac, and carotid arteries. Radiology 2002;224(2): 529-35.
196. Fuster V, Falk E, Fallon JT, Badimon L, Chesebro JH, Badimon JJ. The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Thromb Haemost 1995;74(1): 552-9.
197. Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J. Platelet activation is increased in peripheral arterial disease. J Vasc Surg 2003;38(1): 99-103.
198. Heiss HW, Just H, Middleton D, Deichsel G. Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. Angiology 1990;41(4): 263-9.
199. Platelet inhibition with ASA/dipyridamole after percutaneous balloon angioplasty in patients with symptomatic lower limb arterial disease. A prospective double-blind trial. Study group on pharmacological treatment after PTA. Eur J Vasc Surg 1994;8(1): 83-8.
200. Hess H, Muller-Fassbender H, Ingrisch H, Mietaschk A. [Prevention of re-occlusion after re canalisation of occluded arteries by the catheter method (author's transl)]. Dtsch Med Wochenschr 1978;103(50): 1994-7.
201. Dorffler-Melly J, Koopman MM, Prins MH, Buller HR. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev 2005(1): CD002071.
202. Ranke C, Creutzig A, Luska G, Wagner HH, Galanski M, Bode-Boger S, Frolich J, Avenarius HJ, Hecker H, K AL. Controlled trial of high- versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease. Clin Investig 1994;72(9): 673-80.
203. Weichert W, Meents H, Abt K, Lieb H, Hach W, Krzywanek HJ, Breddin HK. Acetylsalicylic acid - reocclusion - prophylaxis after angioplasty (ARPA-study). A randomized double-blind trial of two different dosages of ASA in patients with peripheral occlusive arterial disease. Vasa 1994;23(1): 57-65.
204. Minar E, Ahmadi A, Koppensteiner R, Maca T, Stumpflen A, Ugurluoglu A, Ehringer H. Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty. Circulation 1995; 91(8): 2167-73.
205. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339(23): 1665-71.
206. Dietz R, Rauch B. Leitlinie zur Diagnose und Behandlung der chronischen koronaren Herzerkrankung der Deutschen Gesellschaft für Kardiologie - Herzund Kreislaufforschung (DGK). In Kooperation mit der Deutschen Gesellschaft für Prävention und Rehabilitation von Herz- Kreislauferkrankungen (DGPR) und der Deutschen Gesellschaft für Thorax-, Herz- und Gefäßchirurgie (DGTHG). Z Kardiol 2003;92: 501-21.
207. Edmondson RA, Cohen AT, Das SK, Wagner MB, Kakkar VV. Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 1994;344(8927): 914-8.
208. Strecker EP, Gottmann D, Boos IB, Vetter S. Low-molecular-weight heparin (reviparin) reduces the incidence of femoropopliteal instent stenosis: preliminary results of an ongoing study. Cardiovasc Intervent Radiol 1998;21(5): 375-9.
209. Schweizer J, Muller A, Forkmann L, Hellner G, Kirch W. Potential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplasty. Angiology 2001;52(10): 659-69.
210. Koppensteiner R, Spring S, Amann-Vesti BR, Meier T, Pfammatter T, Rousson V, Banyai M, van der Loo B. Low-molecularweight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial. J Vasc Surg 2006;44(6): 1247-53.
211. Do DD, Mahler F. Low-dose aspirin combined with dipyridamole versus anticoagulants after femoropopliteal percutaneous transluminal angioplasty. Radiology 1994;193(2): 567-71.
212. Pilger E, Lammer J, Bertuch H, Stark G, Decrinis M, Pfeiffer KP, Krejs GJ. Nd: YAG laser with sapphire tip combined with balloon angioplasty in peripheral arterial occlusions. Long-term results. Circulation 1991;83(1): 141-7.
213. Schneider E, Mahler F, Do Dea. Zur Rezidivprophylaxe nach perkutaner transluminaler Angioplastie (PTA): Antikoagulation versus Ticlopidin. VASA 1987;16 (Suppl 20): 355-6.
214. Davies MG, Hagen PO. Pathophysiology of vein graft failure: a review. Eur J Vasc Endovasc Surg 1995;9(1): 7-18.
215. Green RM, Roedersheimer LR, DeWeese JA. Effects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency. Surgery 1982;92(6): 1016-26.
216. Goldman M, McCollum C. A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prothestic femoro-popliteal grafts. J Vasc Surg 1984;18: 217-21.
217. Kohler TR, Kaufman JL, Kacoyanis G, Clowes A, Donaldson MC, Kelly E, Skillman J, Couch NP, Whittemore AD, Mannick JA, et al. Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery 1984;96(3): 462-6.
218. Dorffler-Melly J, Koopman MM, Adam DJ, Buller HR, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev 2003(3): CD000535.
219. Tangelder MJ, Lawson JA, Algra A, Eikelboom BC. Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrain guinal bypass surgery. J Vasc Surg 1999;30(4): 701-9.
220. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet 2000;355(9201): 346-51.
221. Girolami B, Bernardi E, Prins MH, ten Cate JW, Prandoni P, Simioni P, Andreozzi GM, Girolami A, Buller HR. Antiplatelet therapy and other interventions after revascularisation procedures in patients with peripheral arterial disease: a meta-analysis. Eur J Vasc Endovasc Surg 2000;19(4): 370-80.
222. Dorman BH, Elliott BM, Spinale FG, Bailey MK, Walton JS, Robison JG, Brothers TE, Cook MH. Protamine use during peripheral vascular surgery: a prospective randomized trial. J Vasc Surg 1995;22(3): 248-55; discussion 56.
223. Fearn SJ, Parry AD, Picton AJ, Mortimer AJ, McCollum CN. Should heparin be reversed after carotid endarterectomy? A randomised prospective trial. Eur J Vasc Endovasc Surg 1997;13(4): 394-7.
224. Schneider E, Brunner U, Bollinger A. Medikamentöse Rezidivprophylaxe nach femoropoplitealer Arterienrekonstruktion. Angiology 1979;2: 73-7.
225. Deutsche Gesellschaft für Chirurgie DGfU, Deutsche Gesellschaft für Orthopädie und orthopädische Chirurgie, etc. Stationäre und ambulante Thromboembolie-Prophylaxe in der Chirurgie und der perioperativen Medizin. S2-Leitlinie. AWMF 003/001. Internet: http: //www.uni-duesseldorf.de/ AWMF/ll/003-001.htm. Zugriff am 6.12.2008.
226. Sarac TP, Huber TS, Back MR, Ozaki CK, Carlton LM, Flynn TC, Seeger JM. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg 1998;28(3): 446-57.
227. Johnson WC, Williford WO. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 2002;35(3): 413-21.
228. Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A, Sussex B, Liu L, Guzman R, Cina C, Crowell R, Keltai M, Gosselin G. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007;357(3): 217-27.
229. Baldwin ZK, Pearce BJ, Curi MA, Desai TR, McKinsey JF, Bassiouny HS, Katz D, Gewertz BL, Schwartz LB. Limb salvage after infrainguinal bypass graft failure. J Vasc Surg 2004;39(5): 951-7.
230. Garg PK, Tian L, Criqui MH, Liu K, Ferrucci L, Guralnik JM, Tan J, McDermott MM. Physical activity during daily life and mortality in patients with peripheral arterial disease. Circulation 2006;114(3): 242-8.
231. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995;274(12): 975-80.
232. Lundgren F, Dahllof AG, Lundholm K, Schersten T, Volkmann R. Intermittent claudication - surgical reconstruction or physical training? A prospective randomized trial of treatment efficiency. Ann Surg 1989;209(3): 346-55.
233. Bravata DM, Smith-Spangler C, Sundaram V, Gienger AL, Lin N, Lewis R, Stave CD, Olkin I, Sirard JR. Using pedometers to increase physical activity and improve health: a systematic review. JAMA 2007;298(19): 2296-304.
234. Brand W. Ambulante Rehabilitation-Nutzen und Kostenersparnis. Versicherungsmedizin 1995;47: 95-6.
235. Rieger H. Rehabilitation und Begutachtung bei arteriellen Durchblutungsstörungen. In Rieger H, W Schoop Hrsg.): Klinische Angiologie, Springer, Berlin-Heidelberg 1999.
236. Dertwinkel R, Tryba M, Zenz M. Sympathische Reflexdystrophie, Stumpf- und Phantomschmerz. Deutsches Ärzteblatt 1994;91: 1275-81.
237. Holler D. Gesundheitsökonomische Aspekte der Versorgung chronisch Kranker am Beispiel der peripheren arteriellen Verschlusskrankheit. Dissertation, 2004. Hannoveraner Reihe Versicherungswissenschaften. Versicherungswirtschaft, Karlsruhe.
238. Knipfer E. Lebensqualität und Behandlungskosten bei peripherer arterieller Verschlusskrankheit (PAVK). Dissertation, Medizinische Fakultät der Martin-Luther-Universität Halle-Wittenberg, 2007. Internet: http: //sundoc.bibliothek.uni-halle.de/dissonline/07/08H012/.Zugriff am 19.12.2008.